FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)
Completed
The goal of this clinical research study is to learn if the combination of fludarabine, cyclophosphamide, rituximab, and bevacizumab is effective in treating chronic lymphocytic leukemia in patients who have already been treated with chemotherapy. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
All
Trial Updated:
10/05/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Chronic Lymphocytic Leukemia
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
Withdrawn
Primary Objective: 1. To study ex-vivo purging of autologous hematopoietic stem cells that will be used to support high-dose chemotherapy in patients with chronic myelogenous leukemia (CML). Major endpoints are neutrophil engraftment and survival. Secondary Objectives: 1. To evaluate the toxicity of ex-vivo purged autologous cells when used to support high-dose chemotherapy. 2. To evaluate the rate and duration of cytogenetic remissions achieved with this strategy. 3. To determine the time to... Read More
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
08/21/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Completed
The goal of this clinical research study is to learn if intensive chemotherapy, combined with imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by maintenance imatinib mesylate plus chemotherapy for 2 years, followed by imatinib mesylate indefinitely can improve Philadelphia-positive acute lymphoblastic leukemia. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
15 years and above
Trial Updated:
08/19/2015
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Leukemia
Study of Bortezomib in Combination With Cyclophosphamide and Rituximab
Completed
The goal of this clinical research study is to learn if bortezomib when given in combination with cyclophosphamide and rituximab can help to control mantle cell lymphoma. The safety of this drug combination will also continue to be studied.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/31/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Mantle Cell Lymphoma, Lymphoma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Completed
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
01/29/2015
Locations: Marcos deLima, MD, Houston, Texas
Conditions: Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
Completed
RATIONALE: Drugs used in chemotherapy, such as fludarabine and cyclophosphamide, use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells can reject the body's normal tissues. Alemtuzumab and tacrolimus may prevent this from happening. PURPOSE: Phase II trial to study the effectiveness of combining fludarabine and cyclophosphami... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/27/2015
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Kidney Cancer
Stage I/II Nasal NK Cell Lymphoma
Terminated
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control stage 1 and/or 2 NK cell lymphoma. The safety of radiation and chemotherapy will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/21/2015
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Phase II Neoadjuvant in Inflammatory Breast Cancer
Terminated
The goal of this clinical research study is to learn how well lapatinib taken alone, followed by taking lapatinib with paclitaxel, and then taking lapatinib with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC75) works to help to control Inflammatory Breast Cancer (IBC). The safety of this drug combination will also be studied.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/04/2014
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
Terminated
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy before surgery may shrink the tumor so that it can be removed. Giving combination chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This phase II trial is studying how well surgery and/or combination chemotherapy work in treating children with fibrosarcoma.
Gender:
ALL
Ages:
2 years and below
Trial Updated:
09/16/2014
Locations: Medical City Dallas Hospital, Dallas, Texas +5 locations
Conditions: Sarcoma
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
Completed
The goal of this clinical research study is to find out how well the drug Zolinza (vorinostat) works in combination with the drug combination called CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) to treat patients with untreated T-cell Non-Hodgkin's Lymphoma (NHL). The safety of these drugs in combination and the best dose of vorinostat when given in combination with CHOP will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/02/2014
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
Completed
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective when combined with radiation therapy for treating medulloblastoma. PURPOSE: Randomized phase III trial to compare two combination chemotherapy treatments plus radiation therapy... Read More
Gender:
ALL
Ages:
Between 3 years and 22 years
Trial Updated:
07/31/2014
Locations: University of Texas - MD Anderson Cancer Center, Houston, Texas
Conditions: Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Hodgkin's or Non-Hodgkin's Lymphoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have recurrent or refractory Hodgkin's lymphoma or non-Hodgkin's lymphoma.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
07/31/2014
Locations: Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas +12 locations
Conditions: Lymphoma